Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
Globe Newswire•03/11/2026•07:30 ET
0
Key Highlights
- ➤Helus Pharma CEO Michael Halstead to join Guggenheim Healthcare Innovation Conference fireside chat
- ➤Webcast scheduled November 9, 2026, at 3:00 p.m. EDT
- ➤HLP003 in Phase 3 development for adjunctive major depressive disorder treatment
- ➤HLP004 in Phase 2 development for generalized anxiety disorder
NEW YORK and TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference taking place in Boston.
The fireside chat will be webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT.
Get started
Create a free account to read the full story.